eligibility_summary
Adults ≥18 with FL grade 1–3a and POD24 after 1L anti‑CD20±chemo (refractory or relapse), exactly 1 prior systemic line, ≥1 measurable lesion >15 mm, WHO PS 0–2 (or >2 if due to FL). Exclude: ≥2 prior lines, grade 3b, CD20‑negative, CNS disease, marrow/liver/renal/cardiac dysfunction not due to FL, active HBV/HCV/EBV or severe infection, recent immunosuppressants/live vaccines, severe antibody allergy, prior allo‑HSCT, recent other cancers, pregnancy/breastfeeding, HIV ok if suppressed, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Mosunetuzumab, a subcutaneous bispecific monoclonal antibody (CD20×CD3) T‑cell engager immunotherapy for follicular lymphoma with early relapse (POD24). Mechanism of action: simultaneously binds CD20 on malignant B cells and CD3 on endogenous T cells to create an immune synapse, triggering TCR/CD3 signaling, T‑cell activation/proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing, resulting in depletion of CD20+ lymphoma cells. Cells/targets: CD20+ follicular B cells and CD3+ T cells. Pathways engaged: T‑cell receptor signaling, immune synapse formation, and cytotoxic effector pathways. Trial: Phase II, single‑arm SC monotherapy, efficacy primary focus versus standard second‑line options.